Naltrexone Blockade of Antidepressant Placebo Effects in MDD

Phase 4, randomised, double-blind trial of naltrexone in major depressive disorder (MDD) (2 arms), sponsored by Marta Peciña. Primary endpoints: BOLD Responses in the rACC Cortex During the Processing of Contextual Cues at Baseline at Day 7 and Naltrexone-induced Changes in BOLD Responses in the rACC Cortex During the Processing of Contextual Cues at Day 7. Started Jul 2017; status: completed.